BioCity Biopharm and AstraZeneca Enter into Collaboration Agreement

BioCity Biopharma and AstraZeneca have entered into a collaborative agreement aimed at conducting a Phase Ib/II clinical study. 

The collaboration between BioCity and AstraZeneca aims to assess the potential of combining BC3402 with durvalumab (IMFINZI) to enhance the clinical outcomes for individuals diagnosed with hepatocellular carcinoma (HCC).

The purpose of this study is to assess the safety and effectiveness of BioCity's BC3402, a monoclonal antibody designed to target TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), in combination with AstraZeneca's anti-PD-L1 monoclonal antibody IMFINZI, also known as durvalumab. 

The focus of this joint research effort is to explore the potential treatment benefits of this combination therapy for patients with advanced hepatocellular carcinoma (HCC) in China.

BC3402 is a highly anti-TIM-3 monoclonal antibody (mAb) that outshines its counterparts in terms of binding affinity, making it a potential best-in-class candidate. This antibody possesses the unique capability to bind to multiple epitopes on TIM-3, a critical immune checkpoint protein. Moreover, BC3402 has demonstrated its effectiveness in blocking the interactions of TIM-3 with important molecules such as CEACAM1, PtdSer, and Gal-9.

Furthermore, BC3402 has showcased remarkable synergistic effects when combined with monoclonal antibodies targeting PD-1 and CTLA-4. These are pivotal targets in the clinical treatment of liver cancer. BC3402 has the potential to enhance the efficacy of immune checkpoint inhibitors, holding promise for more effective liver cancer therapies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!